market access strategy

By Michelle Vitko, Senior Research Analyst Preparing to present data to managed care stakeholders is often health outcomes liaisons' (HOLs) most time-intensive activity. While the exact breakdown of time investment varies from company to company, most...

By Jeremy Spivey, Senior Research Analyst In an effort to expand Chinese citizens' access to certain high-volume pharmaceutical products, the Chinese government has committed to expanding a price-squeezing tendering system to the entire country. The...

By Shaylyn Pike, Senior Research Analyst The managed markets function in the United States has been around for many years. Since the arrival of Medicare, Medicaid and the health insurance industry in its current form, drug and device companies have...

By Ryan McGuire,Senior Research Analyst The megatrend of personalized medicine gained a significant boost of adrenaline recently as Vertex Pharmaceutical's cystic fibrosis drug, Kalydeco (ivacaftor), earned FDA approval. As with much of personalized medicine's...

By Shaylyn Pike,Senior Research Analyst Once upon a time, a brand team's quest ended at marketing approval; revenues would take care of themselves. Fast forward 20 years, and the industry faces a much more challenging road to brand success. Receiving...

Distinct salary bands are emerging for new hire and senior liaisons as the function matures With health outcomes liaisons in high demand, life sciences companies must offer a competitive salary package and a career map to attract and retain effective HOLs, according...

By Shaylyn Pike,Senior Research Analyst New research finds that 50 percent of pharmaceutical companies prefer to launch new products in the U.S. before any other market. Half of the drug manufacturers profiled in a new Cutting Edge Information study...

Drug companies allocated 13 percent of their average total market access budgets to patient-reported outcomes teams this year, according to new benchmarking data from Cutting Edge Information. 57 percent of profiled companies will increase their PRO team budgets...

By Shaylyn Pike,Senior Research Analyst As the European Union attempts to prevent its dissolution as its financial crisis deepens, the life sciences industry watches with concern. If the European economy collapses, so does a significant portion of the...

By Jeremy Spivey,Senior Research Analyst After 10 years of deliberations, a draft of India’s National Pharmaceutical Pricing Policy has been released. Though the document will remain open for comments through the end of November, the final policy is...